903 related articles for article (PubMed ID: 18264087)
1. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Sakai W; Swisher EM; Karlan BY; Agarwal MK; Higgins J; Friedman C; Villegas E; Jacquemont C; Farrugia DJ; Couch FJ; Urban N; Taniguchi T
Nature; 2008 Feb; 451(7182):1116-20. PubMed ID: 18264087
[TBL] [Abstract][Full Text] [Related]
2. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
Sakai W; Swisher EM; Jacquemont C; Chandramohan KV; Couch FJ; Langdon SP; Wurz K; Higgins J; Villegas E; Taniguchi T
Cancer Res; 2009 Aug; 69(16):6381-6. PubMed ID: 19654294
[TBL] [Abstract][Full Text] [Related]
3. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
4. Resistance to therapy caused by intragenic deletion in BRCA2.
Edwards SL; Brough R; Lord CJ; Natrajan R; Vatcheva R; Levine DA; Boyd J; Reis-Filho JS; Ashworth A
Nature; 2008 Feb; 451(7182):1111-5. PubMed ID: 18264088
[TBL] [Abstract][Full Text] [Related]
5. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Johnson N; Johnson SF; Yao W; Li YC; Choi YE; Bernhardy AJ; Wang Y; Capelletti M; Sarosiek KA; Moreau LA; Chowdhury D; Wickramanayake A; Harrell MI; Liu JF; D'Andrea AD; Miron A; Swisher EM; Shapiro GI
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17041-6. PubMed ID: 24085845
[TBL] [Abstract][Full Text] [Related]
6. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Pishvaian MJ; Biankin AV; Bailey P; Chang DK; Laheru D; Wolfgang CL; Brody JR
Br J Cancer; 2017 Apr; 116(8):1021-1026. PubMed ID: 28291774
[TBL] [Abstract][Full Text] [Related]
7. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
Swisher EM; Sakai W; Karlan BY; Wurz K; Urban N; Taniguchi T
Cancer Res; 2008 Apr; 68(8):2581-6. PubMed ID: 18413725
[TBL] [Abstract][Full Text] [Related]
8. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
Norquist B; Wurz KA; Pennil CC; Garcia R; Gross J; Sakai W; Karlan BY; Taniguchi T; Swisher EM
J Clin Oncol; 2011 Aug; 29(22):3008-15. PubMed ID: 21709188
[TBL] [Abstract][Full Text] [Related]
9. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Wang W; Figg WD
Cancer Biol Ther; 2008 Jul; 7(7):1004-5. PubMed ID: 18720553
[TBL] [Abstract][Full Text] [Related]
10. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
Simmons AD; Nguyen M; Pintus E
BMC Cancer; 2020 Mar; 20(1):215. PubMed ID: 32171277
[TBL] [Abstract][Full Text] [Related]
11. Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations.
Park PH; Yamamoto TM; Li H; Alcivar AL; Xia B; Wang Y; Bernhardy AJ; Turner KM; Kossenkov AV; Watson ZL; Behbakht K; Casadei S; Swisher EM; Mischel PS; Johnson N; Bitler BG
Mol Cancer Ther; 2020 Feb; 19(2):602-613. PubMed ID: 31575654
[TBL] [Abstract][Full Text] [Related]
12. Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
Meghani K; Fuchs W; Detappe A; Drané P; Gogola E; Rottenberg S; Jonkers J; Matulonis U; Swisher EM; Konstantinopoulos PA; Chowdhury D
Cell Rep; 2018 Apr; 23(1):100-111. PubMed ID: 29617652
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance caused by reversion mutation.
Ashworth A
Cancer Res; 2008 Dec; 68(24):10021-3. PubMed ID: 19074863
[TBL] [Abstract][Full Text] [Related]
14. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
15. Secondary mutations of BRCA1/2 and drug resistance.
Dhillon KK; Swisher EM; Taniguchi T
Cancer Sci; 2011 Apr; 102(4):663-9. PubMed ID: 21205087
[TBL] [Abstract][Full Text] [Related]
16.
Darabi S; Braxton DR; Xiu J; Carneiro BA; Swensen J; Antonarakis ES; Liu SV; McKay RR; Spetzler D; El-Deiry WS; Demeure MJ
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557020
[No Abstract] [Full Text] [Related]
17. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
Tobalina L; Armenia J; Irving E; O'Connor MJ; Forment JV
Ann Oncol; 2021 Jan; 32(1):103-112. PubMed ID: 33091561
[TBL] [Abstract][Full Text] [Related]
18. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N
Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699
[TBL] [Abstract][Full Text] [Related]
19. Cancer: crossing over to drug resistance.
Livingston DM; Silver DP
Nature; 2008 Feb; 451(7182):1066-7. PubMed ID: 18305536
[No Abstract] [Full Text] [Related]
20. Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4.
Guillemette S; Serra RW; Peng M; Hayes JA; Konstantinopoulos PA; Green MR; Cantor SB
Genes Dev; 2015 Mar; 29(5):489-94. PubMed ID: 25737278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]